Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

Launched by RACHEL MILLER · Mar 17, 2017

Keywords

ClinConnect Summary

This clinical trial is looking at how genetic testing can help doctors choose the best targeted therapies for patients with cancer. The goal is to see if these personalized treatments can improve the length of time patients live without their disease getting worse. This research is part of a larger study and is currently recruiting participants.

To be eligible for this trial, you must be at least 18 years old and have a confirmed cancer diagnosis that has not responded to initial treatments. Patients with certain types of brain tumors can participate if their treatment is stable. Before joining, you will need to have genetic testing done on your tumor, and you must be able to understand and sign a consent form. If you decide to participate, you can expect to receive a targeted therapy chosen based on your unique genetic test results, and your health will be closely monitored throughout the study. It's important to note that pregnant women and those with certain health conditions may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with clinically suspected or histologically confirmed solid or hematological malignancy who have undergone or will undergo genetic testing of their tumor
• • Patients must have failed first-line therapy for their disease (refractory) or have no options for curative therapies.
• • Patients must have either measurable or non-measurable disease.
• • Age ≥18 years.
• • Eastern Cooperative Oncology Group performance status ≤3.
• • Patients with brain metastasis must have had treatment of their brain metastasis completed at least 1 day prior to enrollment and be on stable dose of steroids or off steroids at the time of enrollment.
• • Ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.
• • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician.
• • Pregnant women are excluded from this study.
• • HIV positive patients with CD4 counts below 500 OR who are not on a stable dose of antiretroviral therapy (for at least 1 month prior to registration) are ineligible.